Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated

Should I Take CoQ10 or Idebenone for ADOA Vision Loss?

At a Glance

There is currently no medical consensus supporting CoQ10 or Idebenone (Raxone) for treating Autosomal Dominant Optic Atrophy (ADOA). OTC CoQ10 suffers from severe absorption issues, and studies show Idebenone is largely ineffective for ADOA. Always consult your doctor before taking supplements.

At this time, there is no medical consensus or regulatory approval supporting the use of Coenzyme Q10 (CoQ10) or its pharmaceutical alternative, Idebenone (Raxone), to treat Autosomal Dominant Optic Atrophy (ADOA) [1][2]. While it is completely natural to want to take control of your condition by trying supplements, it is important to understand how they work in the body before starting them. Because ADOA affects the mitochondria, many patients consider high-dose over-the-counter CoQ10. However, due to severe absorption issues and potential drug interactions, you should always consult a neuro-ophthalmologist before starting any supplement regimen.

Understanding CoQ10 and Idebenone

ADOA is primarily caused by mutations in the OPA1 gene, which disrupt the function of mitochondria—the energy-producing centers of your cells [3][4].

  • Coenzyme Q10 (CoQ10) is a naturally occurring molecule that helps mitochondria generate energy.
  • Idebenone (sold under the brand name Raxone) is a synthetic, pharmaceutical-grade drug that is structurally similar to CoQ10 [5][6]. It is designed to act as an antioxidant and bypass certain damaged parts of the mitochondrial energy chain to restore cellular function [7][8].

The Clinical Use of Idebenone

Idebenone is an approved and effective treatment for a different genetic eye condition called Leber Hereditary Optic Neuropathy (LHON) [9][10]. Because both LHON and ADOA are optic neuropathies involving mitochondrial dysfunction, some doctors may consider prescribing Idebenone “off-label” for ADOA.

However, LHON and ADOA are caused by entirely different genetic mechanisms [11]. While Idebenone can help bypass the specific mitochondrial defect found in LHON [7], current research does not support its use for ADOA [12]. In laboratory studies using models of ADOA (OPA1 mutations), Idebenone was found to be largely ineffective at protecting retinal ganglion cells (the nerve cells in the eye) from damage [12].

The Problem with Over-the-Counter CoQ10

Patients often wonder if they can simply buy CoQ10 at the pharmacy to protect their vision. Medical professionals caution against using high-dose CoQ10 (often sold as 100mg to 300mg capsules or more) to self-treat for several major reasons:

  • Poor Absorption: CoQ10 is a highly hydrophobic (water-repelling) molecule, which means it has very poor natural absorption in the human digestive tract [13][14]. Even if you take a large dose, very little of it reaches your bloodstream, and even less can cross into the brain and optic nerve [13][15].
  • Ineffective Formulations: To overcome poor absorption, pharmaceutical researchers have to use advanced delivery systems—like microencapsulation or lipid nanoparticles—to make the drug usable by the body [16][17]. Standard off-the-shelf supplements usually lack these advanced delivery methods [18].
  • Lack of Regulation: Unlike prescription medications, over-the-counter supplements are not strictly regulated. The quality, purity, and actual concentration of CoQ10 can vary wildly between brands [19].

(Note: The small amounts of CoQ10 found in a standard daily multivitamin are generally safe for most people, but they are not sufficient to treat a mitochondrial disease).

Partnering with Your Specialist

Before spending money on large doses of supplements that your body may not even absorb, you need to speak with a neuro-ophthalmologist. Self-medicating with unregulated supplements carries risks, including unexpected interactions with other medications. For example, CoQ10 can interact with blood thinners like Warfarin, altering how they work. Furthermore, if a doctor were to prescribe high doses of pharmaceutical Idebenone off-label, it requires strict monitoring due to the risk of liver enzyme changes—a risk that does not typically apply to standard OTC CoQ10, but highlights the need for careful medical supervision.

While there is no proven supplement to stop ADOA progression, you are not out of options. Your doctor can help you establish a baseline of your visual health, connect you with low-vision rehabilitation services, and discuss whether any clinical trials for targeted gene therapies are appropriate for your unique situation.

Common questions in this guide

Does Idebenone (Raxone) treat ADOA?
While Idebenone is an approved treatment for a different genetic eye condition called LHON, current laboratory research shows it is largely ineffective at protecting nerve cells from ADOA damage. There is no regulatory approval or strong medical consensus for its use in treating ADOA.
Will over-the-counter CoQ10 supplements protect my vision?
High-dose over-the-counter CoQ10 is generally not recommended as a reliable treatment for ADOA. CoQ10 naturally has very poor absorption in the human digestive tract, meaning very little of the supplement actually reaches your bloodstream or optic nerve.
Are there risks to taking high doses of CoQ10?
Yes, self-medicating with unregulated high-dose supplements can carry risks. Over-the-counter CoQ10 can interact with certain prescription medications, such as blood thinners like Warfarin, and alter how they work in your body.
What should I ask my doctor before starting supplements for ADOA?
You should ask your neuro-ophthalmologist if there is any clinical rationale for trying off-label mitochondrial supplements based on your specific genetic mutation. Always ensure your doctor knows about every over-the-counter vitamin or supplement you are taking.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific OPA1 mutation, is there any clinical rationale for trying off-label mitochondrial supplements or medications?
  2. 2.How often should we monitor my visual acuity and retinal nerve fiber layer (RNFL) thickness to track the progression of my ADOA?
  3. 3.Are there any clinical trials for targeted gene therapies that I might qualify for?
  4. 4.Could any over-the-counter supplements I am taking interact with my current medications, such as blood thinners?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

What Is the Difference Between ADOA and LHON?ADOA Clinical Trials: What Are the New Treatments?Is Your Normal Tension Glaucoma Actually ADOA?Why is ADOA More Common in Denmark? | Inciteful MedWhy Does ADOA Cause Blue-Yellow Color Vision Loss?Can You Drive With Autosomal Dominant Optic Atrophy?Does ADOA Affect Peripheral Vision? Symptoms & FactsWill I Go Completely Blind from ADOA?How Does Eccentric Viewing Work for ADOA?Does ADOA Cause Hearing Loss? ADOA Plus ExplainedHow Often Do ADOA Patients Need OCT & Visual Field Tests?Is Autosomal Dominant Optic Atrophy Inherited?What Medications to Avoid with ADOA (Optic Atrophy)?How Do I Manage My Mental Health With an ADOA Diagnosis?What Lifestyle Changes Help ADOA Vision Loss?How Fast Does Vision Loss Progress in ADOA?Why Do ADOA Symptoms Vary in Severity Within Families?

References

References (19)
  1. 1

    Mitochondrial optic neuropathies.

    Carelli V, La Morgia C, Yu-Wai-Man P

    Handbook of clinical neurology 2023; (194()):23-42 doi:10.1016/B978-0-12-821751-1.00010-5.

    PMID: 36813316
  2. 2

    Mitochondrial disorders of the retinal ganglion cells and the optic nerve.

    Finsterer J, Mancuso M, Pareyson D, et al.

    Mitochondrion 2018; (42()):1-10 doi:10.1016/j.mito.2017.10.003.

    PMID: 29054473
  3. 3

    Dominant Optic Atrophy (DOA): Modeling the Kaleidoscopic Roles of OPA1 in Mitochondrial Homeostasis.

    Del Dotto V, Carelli V

    Frontiers in neurology 2021; (12()):681326 doi:10.3389/fneur.2021.681326.

    PMID: 34177786
  4. 4

    Sustained intracellular calcium rise mediates neuronal mitophagy in models of autosomal dominant optic atrophy.

    Zaninello M, Palikaras K, Sotiriou A, et al.

    Cell death and differentiation 2022; (29(1)):167-177 doi:10.1038/s41418-021-00847-3.

    PMID: 34389813
  5. 5

    Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone.

    Blanco LP, Pedersen HL, Wang X, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2020; (72(3)):454-464 doi:10.1002/art.41128.

    PMID: 31566908
  6. 6

    Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy.

    Yu-Wai-Man P, Soiferman D, Moore DG, et al.

    Mitochondrion 2017; (36()):36-42 doi:10.1016/j.mito.2017.01.004.

    PMID: 28093355
  7. 7

    Cardioprotective effects of idebenone do not involve ROS scavenging: Evidence for mitochondrial complex I bypass in ischemia/reperfusion injury.

    Perry JB, Davis GN, Allen ME, et al.

    Journal of molecular and cellular cardiology 2019; (135()):160-171 doi:10.1016/j.yjmcc.2019.08.010.

    PMID: 31445917
  8. 8

    Leber hereditary optic neuropathy: current perspectives.

    Meyerson C, Van Stavern G, McClelland C

    Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):1165-76 doi:10.2147/OPTH.S62021.

    PMID: 26170609
  9. 9

    Therapeutic benefit of idebenone in Leber hereditary optic neuropathy: a systematic review and meta-analysis.

    Ribeiro PVZ, Pari Mitre L, Gauza MM, et al.

    Ophthalmic genetics 2025; (46(6)):517-522 doi:10.1080/13816810.2025.2521647.

    PMID: 40653811
  10. 10

    Evaluation of Visual and Optical Coherence Tomography Outcomes in Patients with Leber's Hereditary Optic Neuropathy Treated with Idebenone.

    Iorga RE, Moraru AD, Munteanu-Dănulescu RS, et al.

    Life (Basel, Switzerland) 2025; (15(8)) doi:10.3390/life15081172.

    PMID: 40868820
  11. 11

    Insights on the Genetic and Phenotypic Complexities of Optic Neuropathies.

    D'Esposito F, Zeppieri M, Cordeiro MF, et al.

    Genes 2024; (15(12)) doi:10.3390/genes15121559.

    PMID: 39766826
  12. 12

    A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function.

    Smith TG, Seto S, Ganne P, Votruba M

    Neuroscience 2016; (319()):92-106.

    PMID: 26820596
  13. 13

    Mitochondrial targeting of coenzyme Q10 in inflammatory bowel disease: mechanisms, challenges, and prospects for clinical application.

    Su Z, He X, Mao F, Chu Y

    International immunopharmacology 2025; (166()):115529 doi:10.1016/j.intimp.2025.115529.

    PMID: 40957166
  14. 14

    Water-soluble coenzyme Q10 provides better protection than lipid-soluble coenzyme Q10 in a rat model of chronic tacrolimus nephropathy.

    Cui S, Luo K, Quan Y, et al.

    The Korean journal of internal medicine 2021; (36(4)):949-961 doi:10.3904/kjim.2020.211.

    PMID: 33430574
  15. 15

    Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery.

    Jones M, Walker D, Ionescu CM, et al.

    Therapeutic delivery 2020; (11(12)):791-805 doi:10.4155/tde-2020-0082.

    PMID: 33225829
  16. 16

    Fortification methods of coenzyme Q10 in yogurt and its health functionality-a review.

    Sarma S, Derose S, Govindarajan N, et al.

    Frontiers in bioscience (Scholar edition) 2021; (13(2)):131-140 doi:10.52586/S557.

    PMID: 34879466
  17. 17

    An Overview on Topical Administration of Carotenoids and Coenzyme Q10 Loaded in Lipid Nanoparticles.

    de Souza Guedes L, Martinez RM, Bou-Chacra NA, et al.

    Antioxidants (Basel, Switzerland) 2021; (10(7)) doi:10.3390/antiox10071034.

    PMID: 34206935
  18. 18

    Bioavailability and Cellular Compatibility of a Novel Coenzyme Q10 Emulgel as an Alternative Oral Delivery System for Patients with Dysphagia: Preliminary Results from a Randomized Study.

    Avila AC, Bernabeu E, Chiappetta D, et al.

    European journal of drug metabolism and pharmacokinetics 2026; (51(1)):39-46 doi:10.1007/s13318-025-00970-3.

    PMID: 41182538
  19. 19

    Stability of Reduced and Oxidized Coenzyme Q10 in Finished Products.

    Temova Rakuša Ž, Kristl A, Roškar R

    Antioxidants (Basel, Switzerland) 2021; (10(3)) doi:10.3390/antiox10030360.

    PMID: 33673604

This page discusses experimental and off-label supplement use for Autosomal Dominant Optic Atrophy (ADOA) for educational purposes only. Always consult your neuro-ophthalmologist before starting any new supplements like CoQ10 or Idebenone.

Get notified when new evidence is published on Autosomal dominant optic atrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.